DOCSLIB.ORG

Recovery from Neutropenia Can Be Predicted by the Immature Reticulocyte Fraction Several Days Before Neutrophil Recovery in Autologous Stem Cell Transplant Recipients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recovery from Neutropenia Can Be Predicted by the Immature Reticulocyte Fraction Several Days Before Neutrophil Recovery in Autologous Stem Cell Transplant Recipients Bone Marrow Transplantation (2006) 37, 403–409 & 2006 Nature Publishing Group All rights reserved 0268-3369/06 $30.00 www.nature.com/bmt ORIGINAL ARTICLE Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients ML Grazziutti1, L Dong1, MH Miceli1, M Cottler-Fox2, SG Krishna1, A Fassas1, F van Rhee1, BM Barlogie1 and EJ Anaissie1 1Myeloma Institute of Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA and 2Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA The duration of neutropenia (absolute neutrophil count Introduction (ANC) p100/ll)identifies cancer patients at risk for infection. A test that precedes ANCX100/ll would be of Infection is a serious complication of antineoplastic therapy clinical value. The immature reticulocyte fraction (IRF) particularly in the setting of profound and prolonged reflects erythroid engraftment and hence a recovering myelosuppression.1 The severity of myelosuppression has marrow. We evaluated the IRF as predictor of marrow been evaluated as absolute neutrophil count (ANC)p100/ recovery among 90 myeloma patients undergoing their ml, absolute monocyte count (AMoC)p100/ml,2,3 expected first and second (75 patients)melphalan-based autologous resolution of neutropenia in o10 days and ‘early evidence stem cell transplantation (Mel-ASCT). The time to IRF of marrow recovery.4 Unfortunately, it is difficult to predict doubling (IRF-D)preceded ANC X100/ll in 99% of time to resolution of neutropenia, and ‘early evidence of patients after the first Mel-ASCT by (mean7s.d.) marrow recovery’4 is not a clearly defined end point. A test 4.2371.96 days and in 97% of the patients after the that can predict marrow recovery in an individual patient second Mel-ASCT by 4.1171.95 days. We validated earlier than ANCX100/ml would be of clinical value. these findings in a group of 117 myeloma patients and 99 An increase in oral mucosal neutrophils precedes patients with various disorders undergoing ASCT with neutrophil recovery by 3 days5 but is time consuming. different conditioning regimens. We also compared the Other predictive tests of marrow recovery include hypophos- time to hypophosphatemia and to absolute monocyte phatemia6 and hypouricemia,7 both of which develop in countX100/ll to the time to ANCX100/ll. These approximately 60% of patients upon marrow recovery6,7 but markers were reached prior to this ANC end point in 55 precede ANCX500/ml by only 2–3 days and can be altered and 25% of patients but were almost always preceded by by phosphate replacement, renal failure and/or allopurinol IRF-D. We conclude that the IRF-D is a simple, therapy. inexpensive and widely available test that can predict Increasing numbers of circulating immature reticulocytes marrow recovery several days before ANCX100/ll. has been proposed as a marker of marrow recovery.8,9 Bone Marrow Transplantation (2006) 37, 403–409. During erythropoiesis, reticulocytes are released into the doi:10.1038/sj.bmt.1705251; published online 9 January circulation where they gradually lose their RNA, mature 2006 and evolve into erythrocytes. A higher proportion of Keywords: neutropenia; autologous stem cell transplant; circulating immature reticulocytes (high RNA content) immature reticulocyte fraction; bone marrow engraftment indicates recovering marrow activity and is quantitated by automated hematology cell analyzers.8,9 The fluorescence intensity of the entire reticulocyte population was initially reported as the reticulocyte maturation index or the mean fluorescent index.10,11 Reticulocytes have now been grouped into low, middle (MFR) or high fluorescent region (HFR) corresponding to the lower, middle and higher RNA content, respectively. The immature reticulocyte fraction Correspondence: Dr EJ Anaissie, Myeloma Institute of Research and Therapy, University of Arkansas for Medical Sciences, 4301 West (IRF) measures the MFR and HFR populations and is Markham Slot 776, Little Rock, AR 72205, USA. more reproducible than the HFR.12 E-mail: [email protected] We compared the time to doubling of IRF (IRF-D) to Preliminary results of this manuscript have been presented in abstract time to ANCX100/ml in 90 consecutive myeloma patients form at the 43rd Annual meeting of the Infectious Disease Society of America. San Francisco, October 6–9, 2005 undergoing melphalan-based tandem autologous stem Received 16 September 2005; revised and accepted 11 November 2005; cell transplantation (Mel-ASCT). The IRF-D was found published online 9 January 2006 to be a reliable predictor of ANC recovery and preceded Immature reticulocytes predict neutrophil recovery ML Grazziutti et al 404 ANCX100/ml by several days in the overwhelming majority Table 1 Kinetics of marrow recovery (immature reticulocyte of patients. We also validated the predictive role of the fraction) in relation to neutrophil engraftment in 99 patients under- IRF-D in two cohorts, one of 99 patients with various going autologous stem cell transplantation for various disorders underlying disorders undergoing ASCT with different according to underlying disease and conditioning regimen conditioning regimens and another of 117 myeloma Underlying disease N Days IRF-D P-value patients who were treated with Mel-ASCT. In this latter preceded group of myeloma patients, we compared the time to IRF- ANC4100/ml X D with the time to AMoC 100/ml and time to a 20% drop Non-Hodgkin’s lymphoma 40 5.3373.36 0.23 in serum phosphate over 24 h to the time to ANCX100/ml. Hodgkin’s disease 21 3.973.3 The effect of red blood cell transfusion and hemoglobin Waldenstrom’s macroglobulinemia 14 4.2172.52 (Hgb) level on IRF was also analyzed for the entire study AL-amyloidosis 10 472.91 7 population. Solid tumors 7 4.71 3.25 Others 8 6.7572.66 Conditioning regimen Patients and methods BEAM 53 4.8173.48 0.48 High-dose melphalan 25 4.2872.59 Others 22 5.4173.03 This study was conducted at the Myeloma Institute for Research and Therapy, the University of Arkansas for Medical Sciences, Little Rock, Arkansas. Institutional BEAM ¼ BCNU, etoposide, cytarabine and melphalan.14 Review Board approval was obtained for this study. Others: BEAM-based ¼ 11 patients (with addition of rituximab, velcade or fludarabine); melphalan-based ¼ five patients (with addition of fludarabine, gemcitabine, others); etoposide plus carboplatin (five patients), cytoxan/ Patient population busulfan (one patient). Derivation set: multiple myeloma, prospective. We con- ducted a prospective evaluation of 90 consecutive patients with newly diagnosed myeloma enrolled in our Total Therapy III protocol (February 2004–April 2005) and who were undergoing Mel-ASCT. The induction phase of Blood cell determinations Total Therapy III consists of two cycles of VDT- For measuring blood cells including the IRF, the Abbott PACE (bortezomib, dexamethasone, thalidomide, cisplatin, Cell-Dyn 4000 cell analyzer, (Abbott Diagnostic, Santa doxorubicin, cyclophosphamide and etoposide) with stem Clara, CA, USA) was used between 1998 and December cell collection followed by tandem Mel-ASCT. All 90 2004, and was subsequently replaced by the Sysmex XE- patients received their first Mel-ASCT and 75 received their 2100 Automated Hematology Analyzer Line (Sysmex second Mel-ASCT at the time of this report. All patients America Inc., Mundelein, IL, USA) (December 2004– had daily ANC and IRF values from day 0 ASCT to current). The ranges of normal IRF values for these two ANCX500/ml. units were 0.13–0.31 and 0.04–0.12, respectively. Validation set – Group 1: multiple myeloma, retrospective. We conducted a retrospective review of the medical records of Definitions 382 consecutive patients (October 1998–December 2002) IRF: Two IRF end points taken after IRF nadir were used: with newly diagnosed myeloma enrolled in our Total (a) IRF doubling time (IRF-D) defined as the first of 2 Therapy II protocol13 which relies on four cycles of consecutive days in which the IRF value doubled and (b) induction chemotherapy followed by tandem Mel-ASCT. IRF normal value (IRF-N) which referred to normalization The 117 patients who had daily ANC, AMoC, serum of the IRF by two consecutive days. phosphate and IRF values from day 0 ASCT to Neutrophil recovery: ANCX100/ml. ANCX500/ml during their first Mel-ASCT were analyzed. Monocyte recovery: AMoCX100/ml. Hypophosphatemia: A 20% drop over 24 h in serum Validation set – Group 2: diseases other than myeloma, phosphate levels (PO4-20% drop). retrospective. We also reviewed the medical records of 188 patients (January 1998–July 2005) who underwent ASCT for diseases other than myeloma and received various Statistical analysis conditioning regimens. Of these patients, 99 had daily IRF All analyses were performed with SAS 9.1 (SAS Institute and ANC values from day 0 ASCT to ANCX500/ml. Inc., Cary, NC, USA). Significant level was chosen as 0.05. The underlying disease for this group of 99 patients We used the Student’s t-test to measure the difference included non-Hodgkin’s lymphoma (40%), Hodgkin’s between time to IRF-D and time to ANCX100/ml and disease (21%), Waldenstrom’s macroglobulinemia (14%), paired Student’s t-test to compare the IRF values before amyloidosis (10%), leukemia, solid tumor and others and after red blood cells transfusion. We used ANOVA to (15%). Conditioning regimens consisted of BEAM test for differences in IRF-D among patients with various (BCNU, etoposide, cytarabine and melphalan)14 (53%), underlying diseases and conditioning regimens (validation melphalan (70–200 mg/m2) (21%) and others (22%) set), and for differences in IRF-D according to Hgb levels (Table 1). divided in tertiles. Bone Marrow Transplantation between time to IRF-Dto IRF-D and among to patients with ANC levels lower than Hgb the levels, other the groups.Mel-ASCT. period As This a latter result of groupderivation the had delayed set significantly time higher of Hgb D the overall 75 and within patientslevels each were undergoing group associated their with of significantly patients second each earlier except group time for to of IRF- the patientstime to and IRF-D overall by (Table dividingWe patients 3).
Load more

Recommended publications
  • Case Report Aggressive Systemic Mastocytosis in Association with Pure Red Cell Aplasia
    Hindawi Case Reports in Hematology Volume 2018, Article ID 6928571, 5 pages https://doi.org/10.1155/2018/6928571 Case Report Aggressive Systemic Mastocytosis in Association with Pure Red Cell Aplasia Dhauna Karam ,1,2 Sean Swiatkowski,1,2 Mamata Ravipati,1,2 and Bharat Agrawal1,2 1Rosalind Franklin University, 3333 Green Bay Road, North Chicago, IL 60064, USA 2Captain James A. Lovell Federal Health Care Center, 3001 Green Bay Road, North Chicago, IL 60064, USA Correspondence should be addressed to Dhauna Karam; [email protected] Received 13 March 2018; Revised 20 May 2018; Accepted 20 June 2018; Published 8 July 2018 Academic Editor: H˚akon Reikvam Copyright © 2018 Dhauna Karam et al. )is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Aggressive systemic mastocytosis (ASM) is characterized by mast cell accumulation in systemic organs. )ough ASM may be associated with other hematological disorders, the association with pure red cell aplasia (PRCA) is rare and has not been reported. Pure red cell aplasia (PRCA) is a syndrome, characterized by normochromic normocytic anemia, reticulocytopenia, and severe erythroid hypoplasia. )e myeloid and megakaryocytic cell lines usually remain normal. Here, we report an unusual case of ASM, presenting in association with PRCA and the management challenges. 1. Introduction and active person; he enjoyed biking and rollerblading. )e above symptoms were very unusual for him. )e patient Aggressive systemic mastocytosis is a rare disorder char- reported intermittent episodes of epistaxis, 3-4 times a week acterized by abnormal accumulation of mast cells in bone since the past month, lasting for a few minutes.
    [Show full text]
  • The Hematological Complications of Alcoholism
    The Hematological Complications of Alcoholism HAROLD S. BALLARD, M.D. Alcohol has numerous adverse effects on the various types of blood cells and their functions. For example, heavy alcohol consumption can cause generalized suppression of blood cell production and the production of structurally abnormal blood cell precursors that cannot mature into functional cells. Alcoholics frequently have defective red blood cells that are destroyed prematurely, possibly resulting in anemia. Alcohol also interferes with the production and function of white blood cells, especially those that defend the body against invading bacteria. Consequently, alcoholics frequently suffer from bacterial infections. Finally, alcohol adversely affects the platelets and other components of the blood-clotting system. Heavy alcohol consumption thus may increase the drinker’s risk of suffering a stroke. KEY WORDS: adverse drug effect; AODE (alcohol and other drug effects); blood function; cell growth and differentiation; erythrocytes; leukocytes; platelets; plasma proteins; bone marrow; anemia; blood coagulation; thrombocytopenia; fibrinolysis; macrophage; monocyte; stroke; bacterial disease; literature review eople who abuse alcohol1 are at both direct and indirect. The direct in the number and function of WBC’s risk for numerous alcohol-related consequences of excessive alcohol increases the drinker’s risk of serious Pmedical complications, includ- consumption include toxic effects on infection, and impaired platelet produc- ing those affecting the blood (i.e., the the bone marrow; the blood cell pre- tion and function interfere with blood cursors; and the mature red blood blood cells as well as proteins present clotting, leading to symptoms ranging in the blood plasma) and the bone cells (RBC’s), white blood cells from a simple nosebleed to bleeding in marrow, where the blood cells are (WBC’s), and platelets.
    [Show full text]
  • The Role of Macrophages in Erythropoiesis and Erythrophagocytosis
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Frontiers - Publisher Connector REVIEW published: 02 February 2017 doi: 10.3389/fimmu.2017.00073 From the Cradle to the Grave: The Role of Macrophages in Erythropoiesis and Erythrophagocytosis Thomas R. L. Klei†, Sanne M. Meinderts†, Timo K. van den Berg and Robin van Bruggen* Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, University of Amsterdam, Amsterdam, Netherlands Erythropoiesis is a highly regulated process where sequential events ensure the proper differentiation of hematopoietic stem cells into, ultimately, red blood cells (RBCs). Macrophages in the bone marrow play an important role in hematopoiesis by providing signals that induce differentiation and proliferation of the earliest committed erythroid progenitors. Subsequent differentiation toward the erythroblast stage is accompanied by the formation of so-called erythroblastic islands where a central macrophage provides further cues to induce erythroblast differentiation, expansion, and hemoglobinization. Edited by: Robert F. Paulson, Finally, erythroblasts extrude their nuclei that are phagocytosed by macrophages Pennsylvania State University, USA whereas the reticulocytes are released into the circulation. While in circulation, RBCs Reviewed by: slowly accumulate damage that is repaired by macrophages of the spleen. Finally, after Xinjian Chen, 120 days of circulation, senescent RBCs are removed from the circulation by splenic and University of Utah, USA Reinhard Obst, liver macrophages. Macrophages are thus important for RBCs throughout their lifespan. Ludwig Maximilian University of Finally, in a range of diseases, the delicate interplay between macrophages and both Munich, Germany developing and mature RBCs is disturbed. Here, we review the current knowledge on *Correspondence: Robin van Bruggen the contribution of macrophages to erythropoiesis and erythrophagocytosis in health [email protected] and disease.
    [Show full text]
  • Complete Blood Count in Primary Care
    Complete Blood Count in Primary Care bpac nz better medicine Editorial Team bpacnz Tony Fraser 10 George Street Professor Murray Tilyard PO Box 6032, Dunedin Clinical Advisory Group phone 03 477 5418 Dr Dave Colquhoun Michele Cray free fax 0800 bpac nz Dr Rosemary Ikram www.bpac.org.nz Dr Peter Jensen Dr Cam Kyle Dr Chris Leathart Dr Lynn McBain Associate Professor Jim Reid Dr David Reith Professor Murray Tilyard Programme Development Team Noni Allison Rachael Clarke Rebecca Didham Terry Ehau Peter Ellison Dr Malcolm Kendall-Smith Dr Anne Marie Tangney Dr Trevor Walker Dr Sharyn Willis Dave Woods Report Development Team Justine Broadley Todd Gillies Lana Johnson Web Gordon Smith Design Michael Crawford Management and Administration Kaye Baldwin Tony Fraser Kyla Letman Professor Murray Tilyard Distribution Zane Lindon Lyn Thomlinson Colleen Witchall All information is intended for use by competent health care professionals and should be utilised in conjunction with © May 2008 pertinent clinical data. Contents Key points/purpose 2 Introduction 2 Background ▪ Haematopoiesis - Cell development 3 ▪ Limitations of reference ranges for the CBC 4 ▪ Borderline abnormal results must be interpreted in clinical context 4 ▪ History and clinical examination 4 White Cells ▪ Neutrophils 5 ▪ Lymphocytes 9 ▪ Monocytes 11 ▪ Basophils 12 ▪ Eosinophils 12 ▪ Platelets 13 Haemoglobin and red cell indices ▪ Low haemoglobin 15 ▪ Microcytic anaemia 15 ▪ Normocytic anaemia 16 ▪ Macrocytic anaemia 17 ▪ High haemoglobin 17 ▪ Other red cell indices 18 Summary Table 19 Glossary 20 This resource is a consensus document, developed with haematology and general practice input. We would like to thank: Dr Liam Fernyhough, Haematologist, Canterbury Health Laboratories Dr Chris Leathart, GP, Christchurch Dr Edward Theakston, Haematologist, Diagnostic Medlab Ltd We would like to acknowledge their advice, expertise and valuable feedback on this document.
    [Show full text]
  • Blood and Immunity
    Chapter Ten BLOOD AND IMMUNITY Chapter Contents 10 Pretest Clinical Aspects of Immunity Blood Chapter Review Immunity Case Studies Word Parts Pertaining to Blood and Immunity Crossword Puzzle Clinical Aspects of Blood Objectives After study of this chapter you should be able to: 1. Describe the composition of the blood plasma. 7. Identify and use roots pertaining to blood 2. Describe and give the functions of the three types of chemistry. blood cells. 8. List and describe the major disorders of the blood. 3. Label pictures of the blood cells. 9. List and describe the major disorders of the 4. Explain the basis of blood types. immune system. 5. Define immunity and list the possible sources of 10. Describe the major tests used to study blood. immunity. 11. Interpret abbreviations used in blood studies. 6. Identify and use roots and suffixes pertaining to the 12. Analyse several case studies involving the blood. blood and immunity. Pretest 1. The scientific name for red blood cells 5. Substances produced by immune cells that is . counteract microorganisms and other foreign 2. The scientific name for white blood cells materials are called . is . 6. A deficiency of hemoglobin results in the disorder 3. Platelets, or thrombocytes, are involved in called . 7. A neoplasm involving overgrowth of white blood 4. The white blood cells active in adaptive immunity cells is called . are the . 225 226 ♦ PART THREE / Body Systems Other 1% Proteins 8% Plasma 55% Water 91% Whole blood Leukocytes and platelets Formed 0.9% elements 45% Erythrocytes 10 99.1% Figure 10-1 Composition of whole blood.
    [Show full text]
  • Flow Cytometry Reticulocyte Counting Using Acridine Orange: Validation of a New Protocol Contagem De Reticulócitos Por Citometria De Fluxo Utilizando
    ORIGINAL ARTICLE J Bras Patol Med Lab, v. 50, n. 3, p. 189-199, junho 2014 Flow cytometry reticulocyte counting using acridine orange: validation of a new protocol Contagem de reticulócitos por citometria de fluxo utilizando acridine orange: validação de um novo protocolo 10.5935/1676-2444.20140014 Karina Augusta Viana1; Maria das Graças Carvalho2; Luci Maria Sant’Ana Dusse3; Aline Caldeira Fernandes4; Renato Sathler Avelar5; Danielle Marquete Vitelli Avelar6; Beatriz Carvalho7; Claudia Maria Franco Ribeiro8; Lis Ribeiro do Valle Antonelli9; Andrea Teixeira10; Olindo Assis Martins Filho11 ABSTRACT Introduction: Currently, the reticulocyte counting is a challenge for clinical laboratories in Brazil, mainly for the ordinary ones, which still use the manual method. This method has some limitations, since it consists of a laborious method, time consuming, with low accuracy. Objectives: This study has developed and evaluated the performance of a New Laboratory Protocol for flow cytometry (FC) reticulocytes counting using acridine orange (AO) as dye, aiming to standardize a more precise, easy, fast implementation, and low cost protocol. After standardization of the New Protocol (FC/AO), it was compared with the manual method. The results were analyzed according to the recommendations of the National Committee for Clinical Laboratory Standards (NCCLS), now known as Clinical and Laboratory Standards Institute (CLSI), to evaluate the interchangeability of methods in linear regression analysis and paired t test, besides other quality control tests. Conclusion: Based on these results concerning to the correlation between the methods and the tests related to quality control, we can admit that FC/AO for reticulocyte counting shows undeniable advantages when compared to the preexisting manual method.
    [Show full text]
  • Essential Omega-3 Fatty Acids Tune Microglial Phagocytosis of Synaptic Elements in the Mouse Developing Brain
    ARTICLE https://doi.org/10.1038/s41467-020-19861-z OPEN Essential omega-3 fatty acids tune microglial phagocytosis of synaptic elements in the mouse developing brain C. Madore1,2,14, Q. Leyrolle1,3,14, L. Morel1,14, M. Rossitto1,14, A. D. Greenhalgh1, J. C. Delpech1, M. Martinat 1, C. Bosch-Bouju1, J. Bourel1, B. Rani 4, C. Lacabanne1, A. Thomazeau 1, K. E. Hopperton5, S. Beccari 6, A. Sere1, A. Aubert1, V. De Smedt-Peyrusse1, C. Lecours7, K. Bisht7, L. Fourgeaud8, S. Gregoire9, L. Bretillon 9, N. Acar9, N. J. Grant10, J. Badaut 11, P. Gressens3,12, A. Sierra 6, O. Butovsky 2,13, M. E. Tremblay 7, ✉ ✉ R. P. Bazinet5, C. Joffre1, A. Nadjar 1 & S. Layé1 1234567890():,; Omega-3 fatty acids (n-3 PUFAs) are essential for the functional maturation of the brain. Westernization of dietary habits in both developed and developing countries is accompanied by a progressive reduction in dietary intake of n-3 PUFAs. Low maternal intake of n-3 PUFAs has been linked to neurodevelopmental diseases in Humans. However, the n-3 PUFAs deficiency-mediated mechanisms affecting the development of the central nervous system are poorly understood. Active microglial engulfment of synapses regulates brain develop- ment. Impaired synaptic pruning is associated with several neurodevelopmental disorders. Here, we identify a molecular mechanism for detrimental effects of low maternal n-3 PUFA intake on hippocampal development in mice. Our results show that maternal dietary n-3 PUFA deficiency increases microglia-mediated phagocytosis of synaptic elements in the rodent developing hippocampus, partly through the activation of 12/15-lipoxygenase (LOX)/ 12-HETE signaling, altering neuronal morphology and affecting cognitive performance of the offspring.
    [Show full text]
  • Reticulated Platelets—Which Functions Have Been Established by in Vivo and in Vitro Data?
    cells Review Reticulated Platelets—Which Functions Have Been Established by In Vivo and In Vitro Data? Muataz Ali Hamad 1,2,3,* , Nancy Schanze 1, Nicolas Schommer 1 , Thomas Nührenberg 4 and Daniel Duerschmied 1 1 Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg im Breisgau, Germany; [email protected] (N.S.); [email protected] (N.S.); [email protected] (D.D.) 2 Spemann Graduate School of Biology and Medicine (SGBM), University of Freiburg, 79104 Freiburg im Breisgau, Germany 3 Faculty of Biology, University of Freiburg, 79104 Freiburg im Breisgau, Germany 4 Department of Cardiology and Angiology II, Heart Center, Faculty of Medicine, University of Freiburg, 79189 Bad Krozingen, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-761-270-70470 Abstract: Reticulated platelets (RP) are the youngest platelet fraction released into the circulation. These immature platelets have increased RNA content, a larger cell volume, more dense granules, higher levels of surface activation markers and are thought to be more reactive compared to their mature counterparts. RP have been associated with cardiovascular disease, diabetes and increased mortality. Yet only a few animal studies investigating RP have been conducted so far and further investigations are warranted. Established methods to count RP are flow cytometry (staining with thiazole orange or SYTO13) or fully automated hematology analyzers (immature platelet fraction, Citation: Hamad, M.A.; Schanze, N.; IPF). IPF has been established as a diagnostic parameter in thrombocytopenia, cardiovascular disease Schommer, N.; Nührenberg, T.; and, in particular, the response to antiplatelet therapy.
    [Show full text]
  • Mastocytosis Report of a Case in a 152-Week-Old Infant with Cutaneous and Generalized Skeletal Changes
    Arch Dis Child: first published as 10.1136/adc.40.214.677 on 1 December 1965. Downloaded from Arch. Dis. Childh., 1965, 40, 677. MASTOCYTOSIS REPORT OF A CASE IN A 152-WEEK-OLD INFANT WITH CUTANEOUS AND GENERALIZED SKELETAL CHANGES BY ARTHUR R. C. COLE From The Princess Margaret Hospital, and Hospital for Sick Children, Toronto, Canada (RECEIVED FOR PUBLICATION APRIL 13, 1965) The evolution of medicine has seen the concept of mastocytosis, which are not common to all patients urticaria pigmentosa, as first described nearly 100 and may not be present at all times in any particular years ago by Nettleship (1869), expand to a wide patient. Among them are hyperhistaminaemia, spectrum of disease extending from the simple hyperhistaminuria, hyperheparinaemia, capillary benign mastocytoma (Marshall, Walker, Lurie, changes, gastro-enteric symptoms, spontaneous Hansen, and Mackenzie, 1957) to the malignant histamine shock, aspirin sensitivity, coagulation generalized fatal mastocytosis (Ellis, 1949). Sagher changes, and abnormalities of lipoprotein metabol- and Even-Paz (1960) cite 15 synonyms which may be ism. Mastocytosis may also occur without cutane- included under this heading. ous lesions and constitutes a diagnostic challenge and Braunstein, 1958; At first the disease was considered to be entirely in (Friedman, Will, Freiman, by copyright. the field of dermatology, and many references come Ende and Cherniss, 1958). from that speciality. However, since Ellis (1949) The surgical removal of an isolated mastocytoma described a necropsy on a fatal case in a male infant, in a patient with generalized symptoms due to excess showing the invasion of many organs by mast cells, histamine release may lead to a dramatic cure of their and Sagher, Cohen, and Schorr (1952), Sagher, complaints.
    [Show full text]
  • Last Month's Slides
    ISSUE 12ISSUE April 2021 This issue Last Month’s Slides P.1 Monthly Case study P.1 Reticulocyte measurement P.2 Morphology webinar P.2 Last Month’s Reticulocyte matrix P.3 Breaking news P.3 Slides March 2021 Slide Summaries Monthly Digital Case study Side 1 Slide 5 Follow up of CLL Expert comment – Evolution of Presentation an atypical CLL with 3/5 Male (65 years old) matures scoring to be compared with the rest of the clinical FBC Results results WBC 17.2*(10^3/mm3) Neutrophils 76.2 % Macrothombocyte Slide 2 RBC 4.27* (10^6/mm3) Lymphocytes 1.8 % Discreet Eosinophilia HGB 108* (g/L) Monocytes 8.8 % HCT 36.4* (%) Eosinophils 4.4 % MCV 85*(fL) Basophils 3.5% Slide 3 MCH 25.3* (pg) Occasional large platelets MCHC 29.7* (g/dL) PLT 413*(10^3/mm3) RDW-SD 87.4 *(fL) Slide 4 RDW-CV 29.2* (%) Discreet Basophilia Slide 5 Multiple alarms on analyser Expert Comment – Dimorphic RBC picture RBC, acanthocytes, Macrothrombocytes, Basophilia Slide review Investigate for Multiple alarms on analyser – represented by * Myeloproliferative disorder Dimorphic RBC, acanthocytes, Howell Jolly Bodies, target cells Basophilia, Macrothrombocytes (see above). Slide 6 Diagnosis Neutrophilia, presence of Myeloproliferative myelocytes, metamyelocytes, promyelocytes, nucleated red blood cells Morphology Webinar: Reticulocyte measurement on HORIBA HORIBA recently hosted a analysers webinar on “An Introduction to Morphology”, which Reticulocytes are immature Red Blood Cells (RBC) that are being constantly released includes a demonstration on from the bone marrow (approx. 2.5 billion red cells/Kg/day). The stages of red cell how to use QSP 2.0 in training.
    [Show full text]
  • UC Davis Dermatology Online Journal
    UC Davis Dermatology Online Journal Title Blastic plasmacytoid dendritic cell neoplasm of the skin associated with myelodysplastic syndrome Permalink https://escholarship.org/uc/item/3b65n3px Journal Dermatology Online Journal, 21(3) Authors Kong, Qing-Tao Zhang, Min Sang, Hong et al. Publication Date 2015 DOI 10.5070/D3213022247 License https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Volume 21 Issue 3 March 2015 Case presentation Blastic plasmacytoid dendritic cell neoplasm of the skin associated with myelodysplastic syndrome QT. Kong, M. Zhang, H. Sang, J Chen, WL. Yan, WX. Hu, DQ. Deng, QM. Xie Dermatology Online Journal 21 (3): 18 Department of Dermatology, Jinling Hospital, Nanjing University, School of Medicine, Nanjing, China 210002 Correspondence: H. Sang Department of Dermatology, Jinling Hospital, Nanjing Univ, Sch Med Nanjing, China, 210002. Phone:+86-25-80860092 Fax:+86-25-84815775 E-mail: [email protected] Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a recently described, rare hematologic malignancy with prominent skin involvement. The prognosis of this disease is poor in most cases, with rapid progression despite chemotherapy administration. The first reported case of this disease was in 1994, and less than 200 cases worldwide have been described in the literature to date. Moreover coexistence of BPDCN and MDS is extremely rare. In this study, we describe a typical patient with BPDCN in China who presented with cutaneous involvement as the first manifestation associated with MDS; a brief review of literature is also given. Key words: plasmacytoid dendritic cell; neoplasm; CD4+ ⁄ CD56+ ⁄ CD123+; myelodysplastic syndrome Case synopsis A 62-year-old man presented with a 4-month history of generalized petechia or ecchymosis and subcutaneous nodules.
    [Show full text]
  • Basic Hematology
    Basic Hematology Neil Harris MD Dept. of Pathology, Immunology and Laboratory Medicine University of Florida College of Medicine Gainesville, FL Presented by AACC and NACB LEARNING OBJECTIVES 1. Define “CBC” 2. Define and explain red cell indices including derived values such as MCV, MCHC and MCH 3. Define and explain erythrocyte sedimentation rate 4. Describe the main cell types observed in peripheral blood. 5. Describe what is meant by the term “differential count”. 6. Describe the distribution & morphology of cells in certain common “Blood Pictures” Clinical Diagnostic Laboratories offer: 1. “CBC” 2. “CBC plus Diff.” [CBC + Differential count] 3. Above ± “Reticulocyte count” What do these terms mean, and how are they used? CBC 1. White Cell count (leukocyte count) 2. Platelet count 3. Red cell count, hemoglobin concentration and red cell indices What Specimen? • Whole blood, uncentrifuged, anticoagulated with EDTA (Purple or lavender cap) Cell Counts • White cells, red cells (erythrocytes) and platelets are counted per unit volume of whole blood. • Unit volume: per cubic millimeter (mm3) which is the same as µL • WBC 4.0-10.0 x 103/cu mm • Platelets 150-450 x 103/cu mm • RBC 4.5-5.9 x 106/cu mm Cell Counts • Unit volume: per liter (SI units). • WBC 4.0-10.0 x 109/L • Platelets 150-450 x 109/L • RBC 4.5-5.9 x 1012/L Hemoglobin & Red Cell Indices 1. Hemoglobin 2. Hematocrit 3. Red cell count 4. Mean cell (corpuscular) volume or MCV 5. Mean cell hemoglobin concentration or MCHC 6. Mean cell hemoglobin content or MCH 7.
    [Show full text]